Skip to main content
See every side of every news story
Get Started
SubscribeLogin
Published • loading... • Updated

Harmony Biosciences: WAKIX Cash Flow Funds Its Own Disruption (NASDAQ:HRMY)

Summary by Seeking Alpha
Harmony Biosciences (HRMY) shifts beyond WAKIX as Q2 revenue jumps 30% and $710M net cash funds a neuroscience pipeline—explore its discounted upside now.

2 Articles

Seeking AlphaSeeking Alpha
Lean Right

Harmony Biosciences: WAKIX Cash Flow Funds Its Own Disruption (NASDAQ:HRMY)

Harmony Biosciences (HRMY) shifts beyond WAKIX as Q2 revenue jumps 30% and $710M net cash funds a neuroscience pipeline—explore its discounted upside now.

·Ra'anana, Israel
Read Full Article
MyChesCoMyChesCo

Harmony Biosciences Reaffirms Outlook After Record WAKIX Sales

PLYMOUTH MEETING, PA — Harmony Biosciences Holdings Inc. (Nasdaq: HRMY) reported preliminary second-quarter WAKIX net product revenue of approximately $261 million, a record for the company, reaffirming its full-year revenue …

Read Full Article
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • 100% of the sources lean Right
100% Right

Factuality Info Icon

To view factuality data please Upgrade to Premium

Ownership

Info Icon

To view ownership data please Upgrade to Vantage

MyChesCo broke the news on Sunday, July 26, 2026.
Too Big Arrow Icon
Sources are mostly out of (0)
Blindspot Title And Logo
Stories disproportionately reported by the Left or the Right

Similar News Topics

Pharma icon

Pharma

Stock Markets icon

Stock Markets

Plymouth Meeting icon

Plymouth Meeting

News
Feed Dots Icon
For You
Search Icon
SearchBlindspot LogoBlindspotLocal